Jaka jest cena za Scilex Holding Company (SCLX)

Cena za Scilex Holding Company (SCLX) wynosi $5.61

Jaka jest kapitalizacja rynkowa dla Scilex Holding Company (SCLX)

Kapitalizacja rynkowa dla Scilex Holding Company (SCLX) wynosi $47.65M

Scilex Holding Company (SCLX) Wskaźnik C/WK

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Rok	Wskaźnik P/B	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/B

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/B	Różnica wskaźnika P/B	Kraj
Eli Lilly and Company LLY.US	31.0864	-	US
Johnson & Johnson JNJ.US	7.4766	-	US
AbbVie Inc. ABBV.US	-74.4354	-	US
Roche Holding AG RO.SW	8.4776	-	CH
Merck & Co., Inc. MRK.US	8.008	-	US

Firma

Wskaźnik P/B

Różnica wskaźnika P/B

Kraj